ACADIA PharmaceuticalsMEX:ACAD 73 Current Ratio is 3.59 as of Mar. 2026, which is 43% below its 10-year median of 6.26. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN357.71 (Fairly Valued). The stock has 9 warning signs investors should review. Among 1,413 Biotechnology companies, ACADIA Pharmaceuticals ranks worse than 52.87% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. ACADIA Pharmaceuticals's current ratio for the quarter that ended in Mar. 2026 was 3.59.
ACADIA Pharmaceuticals has a current ratio of 3.59. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for ACADIA Pharmaceuticals's Current Ratio or its related term are showing as below:
MEX:ACAD'
s Current Ratio Range Over the Past 10 Years
Min: 2.04 Med: 6.26 Max: 15.42
Current: 3.59
During the past 13 years, ACADIA Pharmaceuticals's highest Current Ratio was 15.42. The lowest was 2.04. And the median was 6.26.
MEX:ACAD's Current Ratio is ranked worse than 52.87% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs MEX:ACAD: 3.59
ACADIA Pharmaceuticals (MEX:ACAD) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
ACADIA Pharmaceuticals Current Ratio Related Terms
ACADIA Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ACAD vs EWTX, CRNX, VKTX: Current Ratio Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals (MEX:ACAD) has a Current Ratio of 3.59 as of Mar. 2026. This is 43% below median its historical median of 6.26. Over the past decade, ACADIA Pharmaceuticals' Current Ratio has ranged from 2.04 to 15.42. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #747 out of 1413 companies in the Biotechnology industry, placing it in the top 52.9%.
Is ACADIA Pharmaceuticals' Current Ratio too high?
ACADIA Pharmaceuticals' current Current Ratio of 3.59 is 43% below median its 10-year median of 6.26. Over the past 10 years, this metric has ranged from a low of 2.04 to a high of 15.42. The Biotechnology industry median Current Ratio is 3.89. ACADIA Pharmaceuticals' value of 3.59 is 7.7% below this industry median. Based on the distribution chart, ACADIA Pharmaceuticals ranks #747 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Current Ratio compare to EWTX and CRNX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #747 out of 1413 companies for Current Ratio. This places ACADIA Pharmaceuticals in the lower half of its industry. The industry median Current Ratio is 3.89. ACADIA Pharmaceuticals' value of 3.59 is 7.7% below this benchmark. Historically, ACADIA Pharmaceuticals' own Current Ratio has ranged from 2.04 to 15.42 over the past decade. While the company's 10-year median is 6.26 vs. the industry median of 3.89, ACADIA Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACADIA Pharmaceuticals's current Current Ratio of 3.59 is 7.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current Current Ratio is 3.59, which is 43% below median its own 10-year median of 6.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN357.71, compared to a current price of MXN362.00 — trading 1.2% above its estimated fair value. The current Current Ratio is 3.59, which is 43% below median its 10-year median of 6.26 and 7.7% below the Biotechnology industry median of 3.89. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Current Ratio is 3.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN362.00 is trading 1.2% above its estimated GF Value™ of MXN357.71.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:ACAD:
Current Ratio: 3.59 (43% below median its 10-year median of 6.26)
GF Value™: MXN357.71 vs. price of MXN362.00 (1.2% above fair value)
Industry Position: 7.7% below the Biotechnology median (#747 of 1413)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score
Get the complete analysis for MEX:ACAD
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
